vTv Therapeutics Q3 2026 net loss widens 34% to $11.62 million

Bitget2026/11/05 21:15

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

vTv Therapeutics’ third-quarter 2026 net loss attributable to shareholders widened 34% year-over-year to $11.62 million.
General and administrative expenses rose 33% to $4.9 million on higher share-based compensation and payroll-related expenses.
Cash totaled $77.16 million at September 30, 2026, expected to fund operations well through the anticipated CATT1 topline readout.
Phase 3 CATT1 enrollment completed in October with 166 participants randomized; topline results for the type 1 diabetes treatment are expected mid-2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. vTv Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611051601PRIMZONEFULLFEED9869698) on November 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

vTv Therapeutics Q3 2026 net loss widens 34% to $11.62 million

You may also like

Crypto prices